Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCCПодробнее

Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCCПодробнее

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCCПодробнее

Axitinib plus pembrolizumab in advanced RCCПодробнее

Dr. Rini Explains the Axitinib Integration ProcessПодробнее

Promising results for axitinib and pembrolizumab in advanced renal cell cancerПодробнее

Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCCПодробнее

Dr. Rini on Pembrolizumab Plus Axitinib in RCCПодробнее

Dr. Rini Discusses the VEGF Targeted Agent AxitinibПодробнее

Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCCПодробнее

Dr. Rini on the Results From His Axitinib and Sorafenib TrialПодробнее

Dr. Rini Describes Axitinib's and Sorafenib's Side EffectsПодробнее

Dr. Rini Discusses Tivozanib in Advanced RCCПодробнее

Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCCПодробнее

Pembrolizumab monotherapy and pembro-axitinib for RCCПодробнее

Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCCПодробнее

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell CarcinomaПодробнее

Dr. Rini on Standards of Care for Advanced RCCПодробнее

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCCПодробнее